搜索到 1000 条关于 y97텔SUPERADMAN❤️⊇보험디비문의@ 的文章
-
-
2021.11.11 患者血氧 100% 仍觉呼吸困难？一文解读血氧饱和度
, dyshaemoglobins and other pigments. Anaesthesia 1991; 46:291.7.Mendelson Y. Pulse oximetry... oxygen therapy in ventilator-dependent patients. Chest 1990; 97:1420.15. Perkins
-
-
2020.12.23 发热半月余的骨髓肉芽肿，病原会是什么呢 ？
):12-16.[5] Wang Y, Tang XY, Yuan J, et al. Bone marrow granulomas in a high... (Baltimore),2018,97(4):e9726.[6] Mori N, Ohya H, Oba K, et al. Epithelioid cell
-
-
2020.08.24 利妥昔单抗在淋巴瘤领域的最新研究快讯
3.9 年，2 年 PFS 为 76%(95% CI 58–87)，2 年 OS 为 92%（95%CI：77-97%）（见图 1）。随访期间仅有 1 例患者出现..., Atsuta Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine
-
-
2020.05.27 血栓弹力图在肝移植病人凝血功能和输血治疗管理过程中的应用价值
): 97-104.7.White, H.,et al.The utility of thromboelastography... Coagul Fibrinolysis 2012. 23(4):304-10.8.Kang, Y.G., et al.
-
-
2020.02.19 剖宫产时遇到头孢过敏，抗菌药物该如何选择？
, Zhou Y, Liu J, Blustein J. Trends in Cesarean Delivery Rates in China, 2008-2018.... in cesarean delivery: a systematic review. ActaObstet Gynecol Scand 2018;97:521–535.
-
-
2018.09.25 ESPE 2018 热点主题抢先看 -- 性早熟诊治新进展
, Zhang H, Yang Y. Observational study pelvic ultrasound a useful tool... 2018;97(10):e0092.[3] Lopes MC, Ramos CO, Latronico AC, Mendonça BB, Brito VN.
-
-
2017.09.30 陈立波教授：靶向药物开启晚期甲状腺癌治疗新途径
，可为患者获得更好的生存收益，5 年和 10 年生存率分别达到 97% 和 93%。但在自然病程或治疗过程中，仍有部分患者病灶出现失分化，发展为 ...预防医学杂志, 2014, 48(8): 744-748.[2] Chen L, Shen Y, Luo Q, et al. Response
-
-
2017.01.12 PCI 术后血小板骤减：可能的病因及处理
with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97:426-429.3. Sharma A..., Clark WF, Rock G, Matsumoto M, Fujimura Y, Zheng XL, Chen H, Chen F, Armstrong JM
-
-
2016.09.05 实用锦囊：儿童抽动障碍的药物治疗
syndrome:the current status. Arch Dis Child Educ Pract Ed,2012,97(5):166-175.[3...：assessment．Eur Child Adolesc Psychiatry,2011,20(4):155-171．[5]Hartmann A，Worbe Y
-
-
2016.06.30 神经科的那些病例：连枷臂综合征
例 FAS 的研究发现 FAS 的中数生存期（97 个月）明显比肢体起病和延髓起病的 ALS 患者（分别是 72 个月和 48 个月）长，三种临床表型的 5..., Chen R, Tang L, Liu R, Yang Y, et al. Natural history and clinical features
-
2006.09.06 重症肌无力研究进展周报（2）
, K.Y., et al., Intravenous immunoglobulin suppresses experimental myasthenia gravis: Immunological mechanisms. J Neuroimmunol, 2006. 176(1-2): p. 187-97
-
2012.09.19 首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
首届中国PBPK模拟软件GastroPlus Workshop第二轮通知
北京·2012年5月16-18日
上海·2012年5月21-23日尊敬的老师，您好！生理药代动力学模型（PBPK）在药物研发与监管中得到广泛应用意味着新时代的来临！它改变了动物试验和人体实验传统研究模式流程，指导制药企业项目决策及效率提高；FDA和EMA的使用及推荐，促使国外制药企业及学术单位相关研究者都在学习及掌握PBPK的应用。为促进我国在该领域的发展，力争与全球同步，凡默谷特邀美国Simulations Plus顶尖专家来华授课，让您了解及掌握PBPK知识、获悉国外最新应用、亲授多年使用经验，授课过程将以理论与实践相结合的形式进行。GastroPlus是由美国Simulations Plus公司研发的基于机制性生理模型的药代动力学、药效动力学(PBPK/PD)模拟软件，目前在FDA和几乎所有的全球顶尖制药公司中得到广泛应用，被誉为同类软件中的“黄金标准”。为确保培训效果，限额50人/班，第一轮通知发出后，已得到广大中国用户的积极响应和踊跃报名。报名从速！为何本次GastroPlus Workshop值得您参加？1）药物研发及监管中争相应用PBPK模型的时代已经来临！2）PBPK辅助药物研究可方便指导项目决策、节约成本、缩短时间；3）FDA已广泛采用PBPK模拟来制定法规和对新药及仿制药进行审批；4）FDA及各大制药企业对全球最权威的PBPK模拟软件GastroPlus倍加青睐；5）零距离接触Simulations Plus首席科学家，并参与学习的最新应用案例；6）您可免费获得一个月的GastroPlus软件试用。本次GastroPlus Workshop将让您受益良多：1）制药企业或CRO：有利于您理解您的客户或其他Sites实验方案设计思路、下一阶段决策及实验开展、合理设计实验方案；2）学术研究：启示您开辟新的药代、药剂等研究方向，剖析药物作用机制等；3）临床药理研究：合理设计临床试验方案，不同人群PK/PD研究等；4）法规部门：协助制定新药及仿制药政策和标准。报名方法：请您填写报名回执，并通过Email的方式反馈给我们。Email: training@pharmogo.com报名截止：2012年4月20日(北京培训班)/2012年4月30日(上海培训班)联系人：周伟,电话：021-61638583-8001报名确认：1）报名确认以凡默谷收到款项或报名者提供汇款凭证为准，凡默谷可先提供发票以供报销；2）会务组在接到报名后，将email或电话通知学员培训班相关事项。温馨提醒：学员必须自带已安装好Gastroplus程序的电脑参加培训，现场不提供电脑。
GastroPlus Workshop Course Instructors List
培训班详情：请下载附件参加北京培训班请点击下载：GastroPlus北京培训班第二轮通知/BeiJing GastroPlus-Intro-Workshop 2nd Notice参加北京培训班请点击下载：GastroPlus上海培训班第二轮通知/ShangHai GastroPlus-Intro-Workshop 2nd Notice
Michael B. Bolger
Chief Scientist
Simulations Plus Inc.
Dr. Bolger is Chief Scientist at Simulations Plus, he oversees a team of scientist / programmers at Simulations Plus, Inc. (Lancaster, CA) in the development of software programs (ADMET Predictor/Modeler, MedChem Studio/Designer, GastroPlus, DDDPlus, and MembranePlus) for estimation of biopharmaceutical properties, simulations of absorption and bioavailability, automated generation QSP/AR model building, in vitro dissolution, and cell culture permeability simulation.
As a faculty member at USC School of Pharmacy, his research was supported by several NIH basic science research grants and he published over 50 peer-reviewed publications. From 1989-1991 he served as a FDA National Science Advisor. He has served as a reviewer for numerous scientific publications. He is currently Adjunct Associate Professor of Pharmaceutical Sciences at USC.
Haiying Zhou, Ph.D.
Senior Scientist II
Simulations Plus Inc.
Dr. Zhou is Senior Scientist II at Simulations Plus, she focused on the development of modeling and simulation software for quantitative understanding of the pharmacokinetics and pharmacodynamics of drug candidates (GastroPlus), in vitro dissolution of active pharmaceutical ingredients and formulation excipients under various experimental conditions (DDDPlus). She received her M.S. degree in automation from East China University of Science and Technology (ECUST) in 2002 and her Ph.D in Biomedical Engineering from Case Western Reserve University (CWRU) in 2009. Her research interests in CWRU include multi-scale mathematical modeling of gas transport and cellular metabolism with emphasis on the metabolic regulation during different conditions, e.g. hypoxia and exercise.
John DiBella
Vice President of Marketing Simulations Plus Inc.
John DiBella is the Director – Marketing & Sales at Simulations Plus, He joined Simulations Plus in 2003 and has spent time working on the development of GastroPlus? and DDDPlus? software and consulting projects. Now, he leads the marketing & sales activities for the company while continuing to travel the world hosting training seminars.John obtained B.S. and M.S. degrees (with honors) in Biomedical Engineering from Case Western Reserve University in 2003. His graduate research was focused on computational modeling of physiological systems.